RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)
Dr. Jack Cush reviews the news, journal reports and cautions regarding COVID-19
RheumNow Podcast – Booster Shots for COVID (8.13.2021)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)
Dr Jack Cush reviews the news, journal reports and FDA approvals from the past week on RheumNow.com
Rheumatic Flares Uncommon After COVID Vax
MedPage Today
Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found.
RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)
Dr Jack Cush reviews rheumatology and COVID news from the past week on RheumNow.com.
Shingles Risk with JAK Inhibitors and Other Biologics
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
DMARD Effects on COVID-19 Outcomes
Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drug
Potential Birth Defects with Hydroxychloroquine
Hydroxychloroquine (HCQ) is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use.
ICYMI: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease
Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul
ACR Stands Against Insurer Mandated Infusion Locations
ACR
The American College of Rheumatology (ACR) has released an updated position statement on patient safety and site of service for biologics outlining several reasons why the ACR strongly believes infusions should be administered in a monitored health care setting with onsite supervision by a provid
RheumNow Podcast - Best of EULAR 2021
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Social
Join RheumNow Live in person or virtually on 3/18 and 3/19. This meeting is unlike any other meeting you attended.
But don't take our word for it, last year's attendees say:
"Great conference. Best in the last year. I did Hopkins, CCR, and ACR too"
https://t.co/Im6xStFwOw https://t.co/NhdbkNo1jl
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Autoimmune Dz may be assoc w/ new-onset Atrial Fibrillation, esp in women. Population-based UK Biobank found significant increases for AFib in Rheumatic fever w/o CVD (HR 1.47), Crohn’ (1.23), UC(1.17), RA (1.39), PAN (1.82), SLE (1.82), PSS (2.32) https://t.co/rpIiztUfg9 https://t.co/FWmLiZ6x1S
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Join us for RheumNow Live this March 18-19 in Dallas, TX! We're not like other meetings--we're answering the questions you want answered.
RNL is a meeting to engage your mind and change your practice. Join us in-person or virtually!
https://t.co/bMphD12Bie https://t.co/Hx0uHAIUWd
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Best of 2022: Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines
https://t.co/Swf5kq6VtG https://t.co/UTIaCFpAX6
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
73-87% of autoimmune (RA, SLE, UCTD, APL) pts used HCQ during pregnancy. HCQ significantly reduced pre-eclampsia (20% vs 9%), early-onset pre-eclampsia (8% vs 2.5%), 2nd/3rd trimester pregnancy loss (3% vs. 0.6%) https://t.co/CF5ivHeCmY https://t.co/CYqaCCuZJz
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 9 months ago
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies
Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease.
https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 9 months ago
Follow us on LinkedIn too!
https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 9 months ago
Impressive free read and review of Neutrophils and Netosis in Autoimmune and Autoinflammatory disorders (Nature Reviews) from Kapland & Wigerblad at the NIH. https://t.co/w4cIwcQMkt https://t.co/ReA9xM2X4j
Dr. John Cush @RheumNow ( View Tweet )
2 years 9 months ago
Are we giving enough HCQ?🤔
Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48)
#ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim
sheila @RHEUMarampa ( View Tweet )
2 years 10 months ago
#ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT showed discordance (12-30%).When discordant, SRI-4 classified more pts as responders vs BICLA. Concordance higher at 52 vs 24 wks. Vital to interpret both outcomes @RheumNow https://t.co/prSfTrv0E8
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 10 months ago
